About us News Facilities People Research
 
 

Funding Sources

The Prostate Centre at Vancouver General has a strong funding base which provides both infrastructure and research support. Through an aggressive fund raising campaign, the VGH and UBC Hospital Foundation has already raised $41 Million towards a goal of $45 Million. In addition, the senior investigators have brought in more than $15 Million in grant and industrial funding in the past 5 years. The funds raised by the Foundation are used to provide infrastructure support for the 9 principal investigators as well as a staff complement of over 70, including post-doctoral and clinical fellows, graduate students, co-op students, clinical research nurses, technicians and support staff. In addition to basic scientific projects ranging from molecular biology to functional genomics, our research programs encompass clinical trials, socio-behavioral studies and research into complementary and alternative medicine. Some of the funds raised by the Foundation are used to establish endowment funds which will generate interest income to support the Prostate Centre's operations in the future. To date, two such funds have been established. The Prostate Centre Endowment Fund will be allowed to grow as time goes on. The interest from the George R. Richards Endowment for Prostate Science is used to fund the salary of a promising young scientist within the Prostate Centre. Dr.Michael Cox was named the first recipient of the George R. Richards Endowment for Science Award in 2001.

The creation of the Vancouver Centre of Excellence for Prostate Cancer by Health Canada in 1999 contributed significant infrastructure support and provided seed money for new research initiatives. The renewal of the NCIC/Terry Fox Foundation Program Grant for Prostate Cancer Progression in 2001 provides a stable funding base for the next 5 years.


A number of pharmaceutical and industrial partners continue to provide support for clinical trials and basic research. These include Abbott Laboratories, Astra Zeneca, Berlex Pharmaceuticals, Pfizer Canada, Boehringer-Ingelheim Canada, Inflazyme Pharmaceutics, Genentech Inc. and many others.

Grants and publications

The measure of success for researchers is the number of grants and publications which they generate on an annual basis.

Since 1998, our principal investigators have been authors on 151 papers published in significant peer-reviewed journals such as Cancer Research, Clinical Cancer Research, Journal of the National Cancer Institute, Endocrinology, Journal of Biochemistry, the New England Journal of Medicine, Molecular Endocrinology, the Journal of Urology, Cancer, the Journal of Steroid Biochemistry & Molecular Biology, the Journal of Cellular Biochemistry, the Prostate, Urology, the CMAJ and the British Journal of Urology. More than 15 additional manuscripts have recently been submitted for publication. (see publications section)

The scientists who joined the team in 1999 and 2000 have already received significant grant funding and have begun publications on the work they have done at the Prostate Centre. In the past two years, these scientists have received over $350,000 in grant funding as principal investigators and participate in projects totalling nearly $1 Million in additional funding for projects ranging from community education to analysis of complementary therapies.

Biotech companies

Four patents describing antisense therapies targeting 4 novel genes involved in progression of prostate and other malignancies have been submitted, with more under development. The assembled multidisciplinary team of basic and clinical scientists seamlessly span the spectrum of fundamental research and discovery, preclinical proof of principle, and clinical Phase I through Phase III trials. To facilitate development of the patented therapies through clinical trial, Dr. Martin Gleave, Director of Clinical Research at the Prostate Centre, has founded OncoGeneX Technologies Inc., an early stage biotechnology company that will help initiate clinical trials with our lead compound.

A second Vancouver-based functional genomics company, Genexyn Pharmaceuticals Inc. was founded in 1999 to commercialize novel, proprietary functional genomics platform technologies that provide tools aimed at enhancing the speed and efficiency of discovery and validation of targets for drug- and antibody-based human therapeutics. These functional genomics platform technologies are the subjects of patent applications made by the University of British Columbia relating to technologies developed by Dr. Christopher Ong.

 

Prostate Centre Research Activities

NCIC/Terry Fox Foundation Program Grant

The Prostate Centre has a number of inter-linked research projects underway (see attached). The projects listed below form the platform for the Terry Fox/NCIC Program Grant on Prostate Cancer Progression. This grant was initially awarded to Dr. Paul Rennie and his team of investigators in 1998 and it was awarded a five-year renewal, totalling over $6 million dollars, in July 2001.

Each of these projects has its own unique approach but all are geared towards understanding the molecular and genetic mechanisms responsible for prostate disease and, ultimately, using that information to develop therapies for improved treatments. All of these projects are linked by Core components (Molecular Biology, Pathology and Tumour Models) which form the structural base for the NCIC/Terry Fox Foundation Program Grant. The current research projects are:

Prostate-tissue specific determinants for gene expression.

The concept of using a tissue-specific gene promoter to express a "therapeutic" gene in prostate cancers offers an attractive way of potentially targeting locally advanced and metastatic tumours for eradication or control. This project is geared towards developing a gene delivery system based on a herpes virus carrier.
Principal Investigator: Dr. Paul Rennie
Co-investigators: Dr. W. Jia, Dr. C. Nelson, Dr. J. Ausio

Identification and functional analysis of genes expressed during prostate cancer progression using array technology.

In order to understand the mechanisms of the transition to hormone independent tumour growth, we must identify and investigate the underlying genes responsible for this cellular behavior. This project uses high-density gene array technology to identify and characterize the genes which are the fundamental cause of the transition from androgen dependence to androgen independence. This will ultimately provide better diagnostic tools and treatment strategies for advanced prostate cancer.
Principal Investigator: Dr. Colleen Nelson

Role of Integrin-linked Kinase (ILK) in prostate cancer progression.
As prostate cancer progresses, the gene encoding a protein called PTEN becomes mutated and inactivated in greater than 50% of cases. We have made considerable progress in understanding how PTEN works and have identified the protein that PTEN regulates, called ILK. This project investigates the roles of proteins involved in the regulation of adhesion-dependent cell growth.
Principal Investigator: Dr. Shoukat Dedhar

Growth factor and signaling pathways involved in program cancer progression.

The primary problem facing development of effective treatments for advanced prostate cancer is determining the molecular mechanism(s) that underlie acquisition of androgen independence during disease progression. This project addresses the role of aberrantly expressed insulin-like growth factors in allowing prostate tumours to survive hormone withdrawal therapy. These studies will compare how tumor cells respond to these growth factors in the presence or absence of testosterone and will identify the cellular changes that allow prostate tumor cells to become testosterone independent. These results will help us understand how specific signaling events contribute to survival and proliferation of tumor cells faced with treatments that kill normal prostate and early-stage cancer cells.
Principal Investigator: Dr. Michael Cox
Co-investigator: Dr. M. Gleave

Molecular Basis for Apoptotic Resistance: Studies of Clusterin/TRPM-2 and Other Anti-apoptotic Genes Induced during Androgen-Independent Progression.

Our studies have established a role for clusterin as a cell survival gene that is increased after hormone therapy and taxol chemotherapy to inhibit tumour cell death after hormone or chemotherapy. Inhibition of clusterin using antisense clusterin drugs results in a more rapid regression of tumors and a significant delay of emergence of androgen independent recurrent tumours, and also synergistically enhances the cytotoxic effects of various chemotherapy agents, including taxol and mitoxanthrone. This project investigates how some proteins, such as clusterin, can block cell death signals to prostate tumours and make them more resistant to chemotherapy.
Principal Investigator: Dr. Martin Gleave
Co-investigators: Dr. P. Rennie, Dr. C. Ong, Dr. C. Nelson

Neuroendocrine differentiation and prostate tumour progression.

This project focuses on neuroendocrine (NE) cells of the prostate and their potential role in the development of androgen independence by prostate tumors. The goals is to identify the signaling pathways that act to increase the number of neuroendocrine cells in prostate tumours, which is often indicative of increased tumour aggressiveness and progression towards androgen independence.
Principal Investigator: Dr. Michael Cox
Co-Investigator: Dr. M. Gleave

Multitarget combination therapy to delay progression to androgen independence.

This project intends to build upon our previous work involving adaptive/epigenetic mechanisms of hormone-independent progression and the ability of intermittent androgen suppression (IAS) to delay progression. We hypothesize that integration of combination therapies that target specific phases of each IAS cycle will prolong the length of each IAS cycle, thereby delaying progression and prolonging survival. We plan to integrate agents that enhance tumour cell death, reduce tumour cell growth rates provide cytotoxic gene therapy. Results from these studies will provide the pre-clinical proof of principle for testing combination therapies in clinical trials in men with prostate cancer.
Principal Investigator: Dr. Martin Gleave
Co-Investigators: Dr. P. Rennie, Dr. K. Chi, Dr. C. Nelson

Core Facility

The close relationship between the projects facilitated a rapid exchange of knowledge and technology and provided an excellent opportunity to pool some of our resources. This resulted in the creation of a shared multi-component Core Facility to provide an enriched, technologically state-of-the-art environment for specialized training in prostate cancer research. There are three major components: Molecular Biology, Animal Models, and Pathology. The Molecular Biology Core provides services which include cDNA macro- and micro-array fabrication and analysis, recombinant DNA procedures, site-directed mutagenesis, DNA sequencing, preparation of recombinant proteins, mRNA and protein expression analyses, and viral propagation. The Molecular Biology Core also serves as a repository for biologicals, molecular reagents, and genetic samples pertinent to prostate cancer studies. In addition, it provides on-site training in molecular biology techniques to graduate students and post-doctoral fellows. The Animal Model Core, is responsible for breeding of transgenic, nude, SCID and DDS mice as well as propagating, harvesting, and banking of Shionogi and LNCaP tumours. The Pathology Core has at its hub a human prostate tumour bank which currently is the largest of its kind in Canada. Radical prostatectomy, resection, and biopsy specimens from normal, hyperplastic, and neoplastic prostates are catalogued and banked together with corresponding blood cells, serum, and patient data.

Health Canada Infrastructure Funded Programs

Gene Array Facility

The Prostate Centre at VGH has established a Gene Array Facility which is the first in British Columbia and only the second of its kind in Canada. This cutting-edge technology allows for the preparation and analysis of "gene chips" which each have up to 30,000 genes on a single microscope slide. Because the isolation, printing and reading of specific genes is performed with high-throughput robotic equipment, the time, cost and labour savings are enormous. With information provided by this new technology, new diagnostic and treatment protocols can be designed which are tailored for the cancers of individual patients. Owing to its uniqueness, there is enormous interest in the scientific and medical community with regard to potential applications for many diseases. Although the Gene Microarray Facility was installed primarily for prostate disease research, it will be made available to other BC scientists to further their genomic research as it has recently been designated as the Genome BC Array Facility, under the direction of Dr. Colleen Nelson.

Magnetic Resonance Imaging Program

The Prostate Centre initiated a Magnetic Resonance Imaging program to do preliminary research on animal model systems which will hopefully lead to evaluation of human tissue, in vitro and in vivo, within the next one to two years. The MRI service has since become an integral part of our infrastructure, allowing us to view tumours and evaluate tumour growth in living animals. The ability to study prostate cancers prior to and during treatment is of incalculable scientific benefit. Our researchers will work closely with a number of other scientists from such disciplines as Radiology, Physics, Zoology, Radiation Oncology, Pathology and others from within and without UBC. The ultimate goal is development of non-invasive diagnostic and prognostic imaging technology for prostate cancer.

Canadian Prostate Cancer Research Initiative

Training and Education Centre Grant

In February 2001, the Canadian Prostate Cancer Research Initiative awarded a 3-year grant of $600,000 to the Prostate Centre at VGH to allow the creation of a Training and Education Centre for Prostate Cancer Research. Under the leadership of Dr. Michael Cox and Dr. Martin Gleave, this Training Centre is only one of two approved in Canada. The establishment of the Prostate Centre's Training and Education Centre is a first step towards encouraging young students to seek their advanced education in Canada and young scientists to pursue careers in Canada. The end result will be an increase in the critical mass of Canadian independent investigators with an interest in prostate cancer. Over the next three years, we plan to hire 5 Clinical Research Fellows, 3 Post-doctoral Fellows, 3 Graduate students and will be providing funding for 4 Medical Student Summer Fellowships.

Prostate Network Grant

In September 2001, the Canadian Prostate Cancer Initiative announced funding for the creation of the Canadian Molecular and Micronutrient Research Prostate Cancer Network, which links leading Canadian doctors and researchers involved in prostate cancer across Canada. The network includes doctors and scientists from the Prostate Centre (Dr. Martin Gleave and Dr. Paul Rennie), McGill University (Dr. Michael Pollak of Sir Mortimer B. Davis-Jewish General Hospital), and the University of Toronto (Dr. Rob Bristow, Dr. Rama Khokha and Dr. Jeremy Squire of University Health Network, Dr. Neil Fleshner and Dr. Lawrence Klotz of Sunnybrook and Women's Health Sciences Centre). The number of network participants from across Canada is expected to grow with time.

The network is designed to facilitate state-of-the-art genetic and cellular testing of prostate cancer patients to improve the diagnosis and treatment of prostate cancer. The initial cross-Canada collaborations will ask which dietary or genetic factors lead to acquiring prostate cancer and which factors determine why certain patients have more aggressive or resistant cancers than others. These molecular studies will lead to novel therapies, such as gene therapy, which are hoped will prevent and cure prostate cancer.

The Canadian Prostate Cancer Research Initiative has agreed to fund just over $3 million during a five year period, with much of that coming during the "ramp up" stage of the first three years.

Health Canada Research Projects

Analysis of gene cascades regulated by multi-functional transcription factor YB-1 during prostate cancer progression.
Principal Investigator: Dr. Colleen Nelson
Co-investigators: Dr. M. Gleave, Dr. C. Overall, Dr. L. Mayer

We have discovered that YB-1 is upregulated in prostate cancer progression following androgen ablation in the LNCaP tumour model. We have investigated the production of YB-1 in human tumour sample using a human tissue tumour array and found that YB-1 is dramatically upregulated very early in tumour progression, Gleason Grade 2. Yb-1 upregulates the multi-drug resistance gene, p-glycoprotein during this progression. We have made the novel observation that p-gp functions to efflux androgen from the cell and this results in decreased androgen transcriptional activity. We hypothesize from these findings that prostate tumour cells are gradually weaned off of androgen early in progression and may lead to an adaptive advantage upon androgen withdrawal. This work has been submitted to the journals Cancer Research and Molecular Endocrinology for publication.

Identification and Characterization of Proteins that Interact with the Androgen Receptor to Modulate its Activity.
Principal Investigator: Dr. Paul Rennie

The focus of this project is to identify and characterize proteins that bind to the androgen receptor and alter its ability to modulate transcription. This project has made significant progress in the past few months. Specifically, there was an abstract dealing with the binding and activation of the androgen receptor by a neuroendocrine protein which was presented at the most recent annual meeting of the American Association for Cancer Research (April 2002). A manuscript describing these studies is being prepared for submission. Furthermore, a manuscript dealing with the modulation of androgen receptor activity by a GTPase binding protein called RANBPM has recently been submitted to JBC for publication.

Identification and functional characterization of differently expressed genes during androgen withdrawal induced prostate involution.
Principal Investigator: Dr. Chris Ong
Co-investigators: Dr. M. E. Cox, Dr. P. Rennie, Dr. C. Nelson

If we are to have any impact on survival rates, we must target those genes whose aberrant expression are key to the process of progression to androgen independence. In this project, we use high density gene array technology and generation of knock out mice to determine the identity and function of genes critical to tumour regression upon androgen withdrawal. Conditional gene trap vectors have been constructed and the generation of gene trap libraries is ready to commence. A Post-doctoral Fellow, a graduate student and a research technician have been hired and are currently working on this research project.

Phase II study of combination neoadjuvant hormone therapy and weekly OGX-011 prior to radical prostatectomy in patients with localized prostate cancer.
Co-Principal Investigators: Dr. Kim Chi and Dr. Martin Gleave
Co-investigators: Dr. L. Goldenberg, Dr. N. Bruchovsky

After androgen ablation therapy, clusterin expression increases as an adaptive resistance mechanism leading to a decrease in cell death and progression to androgen independent disease. Clusterin over-expression is also a mechanism for resistance to radiation and chemotherapy. This project aims to evaluate whether a compound named OGX-11, in combination with neoadjuvant hormone therapy in patients with prostate cancer prior to radical prostatectomy, can inhibit expression of clusterin in humans and improve the effects of androgen withdrawal therapies.

The formal preclinical pk and toxicology necessary for IND submission to the TPD will be complete in May 2002. GMP production of OGX-011 will be complete in August, with a plan to begin the phase I component of this trial in Sept 2002.

PC-SPES fractionation and prostate cancer treatment.
Principal Investigator: Dr. Emma Guns
Co-investigator: Dr. Don Wilson

Recent clinical studies report that many prostate cancer patients using PC-SPES, a mixture of eight different herbs, enjoy significant reductions in PSA, alleviation of pain associated with bone metastases and inhibition of disease progression. Adverse effects are linked to the potent estrogenicity of the herbal mixture. Individual constituents of PC-SPES are known to have anti-tumor, antimutagenic, chemo-sensitizing and immunomodulatory effects. The estrogen-like activity of PC-SPES is likely to be one mechanism of action responsible for its therapeutic activity. In this project, we propose to determine and distinguish estrogen-independent therapeutic activity from pure estrogenic properties of PC-SPES. To date, we have analyzed five batches of PC-SPES using GC and LC-MS to determine the extent of contamination of our batches with the potent synthetic estrogen, DES. We found 3 out of 5 batches tested contained DES. We have prepared a manuscript reporting our findings which is ready for submission.

This proposal does not intend to search for a single magic bullet amongst the wealth of pharmacologically active chemicals which constitute PC-SPES, but more to understand the active combination in a sense that will allow reformulation and refinement by eliminating estrogenic toxicity whilst optimizing therapy for the treatment of prostate cancer.

Prospective Study Assessing Decision-Making For Men With Prostate Cancer Who Forgo Conventional Treatment And Use Complementary Therapies.
Principal Investigator: Marja Verhoef
Study Director: Margaret White
Co-investigators: Graeme Duncan, Hal Gunn, Darlene Ramsum, Joyce Davison, Karen Cooke

This study is a collaborative effort involving researchers from the Tzu Chi Institute of Complementary Medicine, the Centre for Integrated Healing, the B.C. Cancer Agency, and the Prostate Centre at Vancouver Hospital. The goal of the study is to enroll 50 men with prostate cancer who have refused conventional cancer treatment within one year of diagnosis. They will be followed for three years to assess changes in decision-making about treatment, disease symptoms, quality of life, emotional adjustment, and use of complementary therapies. They will participate in a brief interview and complete a package of questionnaires at the start of the study and at 6, 12, 18, 24 and 36 months. Their PSA level will be documented at diagnosis, and at each follow-up interval over the three year period.

The study was approved by the Clinical Research Ethics Board at the University of British Columbia in March 2002. Pilot testing of the interview guide and accrual procedures is underway. Recruitment procedures have been reviewed and approved at each of the participating institutions. Patient accrual is scheduled to begin by April 15th, 2002.

Evaluating a Decision Support Intervention for Men with Prostate Cancer.
Principal Investigator: Dr. Joyce Davison
Co-investigators: Dr. L. Goldenberg, Dr. M. Gleave, and Dr. L. Degner

The primary objective of this study is to determine if providing individualized information (using a computerized decision aid and counseling) will enable a group of men to assume a more active role in medical decision-making, when compared to a group of men who receive generic information (video and written materials). Secondary objectives include measure the extent to which the intervention will impact on decisional conflict and satisfaction after a treatment decision has been made and quality of life, decisional regret and satisfaction following definitive treatment.

Data collection on this project has begun and approximately 120 men have been enrolled in the study. A research nurse has been trained to do the data collection and a research assistant is entering data as it is collected. The study protocol did not require any changes.

Lipids and hypoxia in prostate cancer progression and diagnosis.
Principal Investigator: Dr. Piotr Kozlowski
Co-investigators: Dr. P. Hochachka, Dr. L. Goldenberg, Dr. S. Chang

The great challenge in the management of prostate cancer is diagnosing the disease at a stage where it is early enough for curative therapy yet not too early to capture "insignificant" cancers. It has been recognized that free fatty acids accumulate as end products of the transformation from normal to malignant prostate epithelial cells. The hypothesis is that redox regulation is the function of this lipid synthesis and that a limited supply of oxygen is a crucial signal triggering malignant transformation. This project will use an animal model of prostate cancer with Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) techniques to investigate the roles of hypoxia and lipid production in prostate cancer progression.

US Department of Defense

The United States Army, through a special research program, announced in February 2001 that they would provide funding of $1 million to Dr. Martin Gleave and Dr. Kim Chi to fund an upcoming clinical study at the Prostate Centre. The study will examine the use of a promising new, anti-cancer drug called OGX-011 (Clusterin Antisense Oligonucleotide) that blocks off the defences of tough, "Survivor" prostate cancer cells. The study will examine the ability of OGX-011 to suppress prostate cancer cells that survive in the body after treatment and believed responsible for causing relapses of the disease. Despite positive first treatments for prostate cancer, remissions are often temporary in the advanced stages of the disease because of the surviving cancer cells. The phase I/II clinical trials with OGX-011 commences in mid-2002, involves 75 patients at the Prostate Centre at VGH and the BC Cancer Agency and one to two years to complete.

Clinical Research Trials

A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression For Patients With Prostate-Specific-Antigen Progression In The Clinical Absence Of Distant Metastases Following Radiotherapy For Prostate Cancer to compare standard continuous hormone treatment with intermittent hormone treatment to determine if intermittent treatment is as effective and if it improves quality of life.

A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression For Patients With Metastatic Prostate Cancer to compare how well patients respond to these two different methods of giving treatment with a LHRH analogue in combination with an anti-androgen drug for the treatment of advanced prostate cancer.

A Double-Blind, Placebo-Controlled, Randomized Study of Combination Vitamin E, Selenium, and Soy Product in Patients with High Grade Prostatic Intraepithelial Neoplasia to determine if soybean derivatives plus Vitamin E and Selenium can prevent the ultimate development of prostate cancer in men with PIN cells.

Randomized, Comparative Study of 3 Months versus 8 Months of Neoadjuvant Combination Therapy with Lupron® Depot® and Euflex® prior to Radical Prostatectomy in Localized Prostate Cancer to evaluate whether the use of this hormone therapy for 8 months prior to radical prostatectomy shrinks the cancer more completely to allow more complete removal compared to 3 months of treatment.

A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Comparative Safety and Efficacy Study of Intravenous Zoledronate (4 and 8 mg) in Prostate Cancer Patients with Metastatic Bone Lesions Receiving Antineoplastic Therapy to examine and compare the effects of Zoledronate to placebo in preventing the bone complications associated with prostate cancer, and to help determine if Zoledronate is effective for the relief of pain due to bone metastases in prostate cancer patients.

A Multicentre, Randomized, Double-Blind Double-Dummy Parallel-Group Study to Compare the Efficacy of GI98745 0.5mg od Versus Finasteride 5mg od for 12 months in the Treatment of Benign Prostatic Hyperplasia (BPH) to determine whether GI198745 will be more effective than Finasteride in reducing a substance in the blood which contributes to prostate growth.

A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety and Efficacy of Neoadjuvant Therapy with GI198745 in Subjects with Localized Prostate Cancer Undergoing Radical Prostatectomy to determine how the study drug GI198745 affects the prostate gland when given for 6 to 10 weeks before radical prostatectomy.

Multicentre, Single-Arm, Open-Label Study of Neoadjuvant Hormone Therapy and Weekly Taxotere Prior to Radical Prostatectomy in Localised Prostate Cancer. An evaluation of a combination of hormone treatment and chemotherapy to improve outcome of radical prostatectomy.

A Phase I Dose Finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, which evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with hormone refractory prostate cancer.

NCIC- A Randomized Phase 2 study of ZD1839 (Iressa) in patients with Hormone Refractory Prostate Cancer.

A Phase III, randomized , Double Blind , Placebo-controlled, study of the safety and efficacy of 10mg of Atrasentan in Men with Metastatic Hormone Refractory Prostate Cancer.

A Phase III , randomized , Double Blind, Placebo-controlled , study of the safety and efficacy of 10mg Atrasentan in men with "Non-metastatic " Hormone Refractory Prostate Cancer.

A Phase III Extension study to evaluate the safety of 10mg Atrasentan in Men with Hormone Refractory Prostate Cancer.

A Randomized Trial of Radical Prostatectomy versus Brachytherapy for Patients with T1c or T2a N0 M0 Prostate Cancer.

Multicentre, single arm, open -label study of combination Neoadjuvant Hormone Therapy and weekly Taxotere prior to Radical Prostatectomy in Localized Prostate Cancer.

An exploratory study of the Intraprostatic Distribution of QLT0074 in patients undergoing Radical Prostatectomy for Prostate Cancer.

Awards

2001


Dr. Michael Cox named recipient of the George Richards Endowment for Prostate Science Award

2001


Dr. Colleen Nelson named as Outstanding Researcher of the Year, Division of Urology, UBC Dept. of Surgery, UBC

2001

 

Dr. Martin Gleave awarded the prestigious William E. Rawls Prize by the National Cancer institute of Canada

2001

 

Dr. Colleen Nelson named as Michael Smith Foundation for Health Research, Senior Scholar

2001

 

Dr. Larry Goldenberg receives Western Urologic Forum Henry M. Weyrauch Award

2001

 

Dr. Sandra Krueckl receives Michael Smith Foundation for Health Research, Trainee Award (Post-doctoral Fellow)

2001

 

Dawn Bradley receives Michael Smith Foundation for Health Research, Trainee Award (Graduate Student)

2001

 

Dr. Sherwin Xie receives US Department of Defense Postdoc Trainee Award

2002

 

Dr. Michael Cox named as Peter Wall Institute Scholar

2002

 

Dr. Chris Ong named as VGH Research Scholarship Award recipient (3-year award)

2002

 

David Mulholland receives CIHR Trainee Award

2002

 

Dr. Michael Cox named as Michael Smith Foundation for Health Research Scholar

2002

 

Dr. Jenny Bryan as Michael Smith Foundation for Health Research Scholar

2002

 

Dr. David Huntsman named as Michael Smith Foundation for Health Research Scholar
2002 Latif Wafa receives Michael Smith Foundation for Health Research, Trainee Award (Graduate Student)

 

     
Quick Links: Home | About us | History of Our Centre | Highlights | Our Goals | Facilities | Our People | Publications | Research
Dr. Cox | Dr. Davison | Dr. Gleave | Dr. Goldenberg | Dr. Guns | Dr. Kowzlowski | Dr. Nelson | Dr. Ong | Dr. Rennie | Gene Array Facility



© Copyright 2000- 2007 The Prostate Centre at Vancouver General Hospital | About this site
Any questions or comments on this page, please contact the webmaster.